Avalo Therapeutics Inc
Ownership
Ownership Structure
Who owns Avalo Therapeutics Inc (AVTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.8% of the shares are freely tradable; institutional investors hold 76.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 9.51 | 5,100,216 | +77.1 | 06/30/2026 |
| BlackRock Inc | 8.14 | 4,365,553 | +1,234.7 | 06/30/2026 |
| Nantahala Capital Management, LLC | 6.94 | 3,724,500 | +201.6 | 06/30/2026 |
| Deep Track Capital, LP | 6.73 | 3,610,000 | +0.0 | 06/30/2026 |
| Caligan Partners LP | 5.90 | 3,163,866 | +93.5 | 06/30/2026 |
| TCG Crossover Management, LLC | 5.63 | 3,017,120 | +308.6 | 06/30/2026 |
| Affinity Asset Advisors, LLC | 5.41 | 2,900,000 | +116.3 | 06/30/2026 |
| State Street Corp | 5.39 | 2,889,287 | +3,932.3 | 06/30/2026 |
| Farallon Capital Management, L.L.C. | 4.66 | 2,498,000 | +172.7 | 06/30/2026 |
| Point72 Asset Management, L.P. | 4.45 | 2,387,026 | +160.6 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Doyle Mittie | Chief Medical Officer | 51,776 | 372,787 $ | Aug 28, 2026 | direct |
| Sullivan Christopher Ryan | Chief Financial Officer | 39,900 | 287,280 $ | Sep 16, 2026 | direct |
| Riley Jennifer | Chief Strategy Officer | 37,041 | 266,695 $ | Aug 11, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 12,394 | 16.33 | 202,437 |
| Sep 16, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 12,394 | 9.88 | 122,453 |
| Sep 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 10,185 | 17.62 | 179,457 |
| Sep 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 10,185 | 8.04 | 81,887 |
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 679 | 20.00 | 13,580 |
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | Other | 679 | 8.04 | 5,459 |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 31,031 | 20.05 | 622,324 |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 31,031 | 9.88 | 306,586 |
| Aug 17, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 1,000 | 20.00 | 20,000 |
| Aug 17, 2026 | Doyle Mittie | Chief Medical Officer | Other | 1,000 | 12.65 | 12,650 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 3,749 | 19.94 | 74,762 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 37,945 | 19.85 | 753,333 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 2,876 | 9.88 | 28,415 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 37,945 | 9.88 | 374,897 |
| Aug 11, 2026 | Riley Jennifer | Chief Strategy Officer | Sell | 2,655 | 19.59 | 52,012 |
| Aug 10, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 679 | 20.00 | 13,580 |
| Aug 10, 2026 | Doyle Mittie | Chief Medical Officer | Other | 679 | 8.04 | 5,459 |
| Jul 27, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 1,000 | 20.00 | 20,000 |
| Jul 27, 2026 | Doyle Mittie | Chief Medical Officer | Other | 1,000 | 12.65 | 12,650 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.